See Graham's ranking
4.0
ADMA Biologics Inc. operates in the healthcare sector, within the biotechnology and biopharmaceutical products subsector, with a focus on the development, manufacturing, and commercialization of human plasma–derived therapies.
Founded by a group of biomedical professionals in the United States, the company was established to meet the demand for specialized immunoglobulins used in the treatment of immunocompromised patients.
The company’s portfolio is primarily composed of plasma-derived medicines, including intravenous and subcutaneous immunoglobulins used to treat primary immunodeficiencies, recurrent infections, and conditions related to immune insufficiency.
Among its most significant products are BIVIGAM, ASCENIV, and other plasma components used in hospital settings.
Its market presence is predominantly North American, with product distribution to hospitals, infusion clinics, immunodeficiency treatment centers, and specialized biological-product networks.
The company also supplies blood banks and plasma-collection centers, integrating with suppliers and distributors throughout the biopharmaceutical sector.
Market factors influencing ADMA’s operations include growing demand for immunoglobulins, stringent regulatory requirements for plasma-derived products, the availability of plasma collection and processing capacity, and competition with global industry players such as Grifols, CSL Behring, and Takeda.
The need for immunological therapies and the rising diagnosis of rare diseases further reinforce the importance of the segment.
The company’s operational structure includes plasma-collection centers, processing units, and manufacturing facilities certified by the U.S. Food and Drug Administration (FDA).
ADMA follows a vertically integrated production model, ranging from plasma collection to fractionation, purification, and final distribution. Specialized teams work across manufacturing, clinical research, quality control, logistics, and regulatory affairs.
The workforce is composed of hundreds of employees distributed across collection centers, production plants, and administrative offices. ADMA Biologics maintains ongoing investments in purification technologies, industrial capacity expansion, and improvements in laboratory processes.
Shares of ADMA Biologics Inc. are traded on Nasdaq under the ticker ADMA.
History and when ADMA Biologics Inc. was created
ADMA Biologics Inc. was founded in 2004 in the United States with the purpose of developing plasma-derived therapies for patients with primary immunodeficiency and other clinical conditions requiring antibody replacement.
In its early years, the company focused on clinical development of specialized immunoglobulins, including laboratory studies and clinical trials conducted in accordance with FDA standards. Following approval of its first biological products, ADMA established a commercial base and began expanding its plasma-collection capacity.
Throughout the 2010s, the company expanded its infrastructure by acquiring manufacturing facilities and licensing fractionation technologies. This period marked the transition from a research-focused organization to a vertically integrated biopharmaceutical company capable of producing and distributing immunoglobulins on a commercial scale.
Historical milestones include regulatory approval of its main therapies, expansion of its plasma-collection network, and technological advancements that increased production capacity. The company’s listing on the stock market through an initial public offering (IPO) further strengthened its ability to invest in new operational capabilities.
Between 2020 and 2024, ADMA Biologics accelerated industrial expansion to meet rising demand for immunoglobulins, modernized its production facilities, strengthened its portfolio of specialized therapies, and expanded distribution agreements.
The period also saw regulatory advances, optimization of plasma-purification processes, and significant growth in the supply of immunological therapies in the North American market.
Additional Information
The Company ADMA Biologics Inc. (United States), is listed on Nasdaq with a market cap of $ 4.11 Billions, having an equity of $ 431.19 Millions.
With a total of 407 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 488.55 Millions, which generated a profit in the amount of $ 209.45 Millions.
As for its main indicators, the Company has a P/E ratio of 19.60, a P/BV ratio of 9.52 and in the last 12 months the Company did not pay dividends.
The Company is traded internationally through the ticker ADMA.
